This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: CVS Bags Apria's Specialty Infusion Business

NEW YORK (The Deal) -- CVS Caremark Corp. (CVS - Get Report) on Wednesday, Nov. 27, said it would acquire the specialty infusion business of Apria Healthcare Group in a deal that is valued at $2.1 billion.

The business to be acquired, Coram, is one of the nation's largest providers of infusion therapies and nutrition services to more than 20,000 patients each month. The Denver-based unit cares for patients via home visits as well as a national network of more than 85 locations.

Infusion therapies are treatments for chronic conditions including immune deficiencies, rheumatoid arthritis, multiple sclerosis and nutritional deficiencies. Costs related to the procedures are often covered under pharmacy benefits, depending on where the treatments take place.

Jon Roberts, president of Woonsocket, R.I.-based CVS's pharmacy services unit, said the deal would be a boost to the CVS business.

Must Read: The Deal: Comcast Faces New Burdens in Time Warner Bid

"Infusion will be a valuable component of our broad specialty pharmacy offering going forward," Roberts said. "Our comprehensive services will enable us to streamline care management for patients as well as their physicians, leading to better health outcomes while avoiding unnecessary costs."

CVS said it expects Coram to generate about $1.4 billion in sales during the first twelve months of ownership.

For Lake Forest, Calif.-based Apria, a Blackstone Group (BX) portfolio company, the deal provides a much needed cash infusion. Moody's Investors Service earlier this month put out a warning concerning the company's liquidity, saying in a report that it expects "that there are not sufficient liquidity sources to meet the company's sizable debt obligations absent a refinancing."

Apria chairman John G. Figueroa, who is also CEO of Coram, in a statement said that "CVS Caremark and Coram share a mutual commitment to provide patients with quality care."

Post-deal Apria will still be a provider of oxygen therapy, sleep apnea products and other services via a network of 500 locations.

Barclays (BCS) is serving as CVS' financial adviser, with Sullivan and Cromwell LLP acting as legal counsel and Dechert handling antitrust matters. Goldman, Sachs & Co. (GS) and Blackstone Advisory Partners acted as financial advisers to Apria, while Simpson Thacher & Bartlett served as legal adviser.

Written By Lou Whiteman

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CVS $105.15 1.20%
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs